Thermo Fisher Scientific Inc.

TMO Healthcare Diagnostics & Research

Thermo Fisher Scientific Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.6 billion, up 3.91% from fiscal 2024. In the quarter to June 2026, revenue grew 10.5%, EPS grew 9.35%, free cash flow grew 51.8% and total debt rose 18.7%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.

690.00 6.49 −0.93%
Market cap
$257.5B
P/E
37.1×
Fwd P/E
23.7×
Dividend yield
0.27%
F-score
5/9
Altman Z
3.84
Beneish M
−2.46
Dividend safety
88/100
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
28.01 34.16 30.66 35.16 28.95 34.03 31.15 35.06 31.38 32.61
Piotroski F-Score
7 4 7 8 8 5 5 5 7 5
P/S ratio
3.11 3.64 3.69 5.09 5.73 6.70 4.83 4.90 4.63 4.90
Altman Z-Score
2.43 2.42 3.10 4.06 4.82 4.27 3.89 3.83 4.06 3.84
Altman Z″-Score (non-manufacturers)
2.58 2.39 3.07 3.49 4.24 3.17 3.41 3.68 3.97 4.01
P/FCF ratio
19.98 21.75 23.46 31.83 27.03 38.61 31.27 29.95 27.13 34.47
Beneish M-Score
(2.45) (2.50) (2.52) (2.51) (2.44) (2.18) (2.50) (2.53) (2.58) (2.46)
P/Operating CF
47.08 40.85 49.95 67.93 55.24 107.00 62.19 56.42 60.40 63.19
Dividend Safety Score
— — — — — — — — — 88
P/B ratio
2.63 3.00 3.26 4.38 5.34 6.43 4.92 4.50 4.01 4.09
Price to Tangible BV
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Sales
3.90 4.48 4.33 5.66 6.00 7.42 5.28 5.44 5.18 5.48
EV/EBITDA
16.92 18.78 17.45 21.05 19.10 23.04 20.15 22.72 21.27 23.20
EV/Operating CF
21.90 23.41 23.24 29.08 23.31 31.22 25.92 27.75 25.64 31.24
EV/FCF
25.12 26.76 27.53 35.42 28.32 42.70 34.21 33.26 30.34 38.54
Quick Ratio
0.87 0.74 1.02 1.09 1.56 0.93 0.98 1.16 1.03 1.25
Current Ratio
1.44 1.34 1.73 1.92 2.13 1.50 1.48 1.75 1.66 1.89
Net Debt/EBITDA
3.46 3.51 2.58 2.14 0.87 2.21 1.73 2.26 2.25 2.45
Debt/Assets
33.48% 33.30% 31.51% 29.25% 27.67% 33.99% 29.76% 31.71% 29.86% 32.49%
Debt/Equity
0.71 0.74 0.64 0.58 0.55 0.79 0.66 0.67 0.59 0.67
Asset Turnover
0.42 0.41 0.43 0.45 0.51 0.48 0.47 0.44 0.44 0.43
Operating CF/Net income
1.61 1.80 1.55 1.35 1.30 1.21 1.32 1.40 1.37 1.17
Capex/Depreciation
(0.24) (0.25) (0.31) (0.39) (0.63) (0.97) (0.66) (0.41) (0.43) (0.53)
Interest Coverage
51.21 5.00 5.67 6.80 14.09 18.71 11.56 4.99 5.28 5.46
ROE
9.43% 9.48% 11.09% 12.91% 19.86% 20.50% 16.37% 13.21% 13.16% 13.02%
ROA
4.66% 4.34% 5.20% 6.45% 10.01% 9.41% 7.23% 6.12% 6.46% 6.46%
ROIC
4.25% 4.31% 5.47% 6.47% 11.25% 9.12% 8.14% 6.13% 6.28% 6.12%
Return on Tangible Assets
42.72% 34.66% 33.99% 35.39% 36.29% 51.47% 39.72% 29.94% 34.98% 27.84%
Average Days of Receivables
68.45 67.69 61.98 62.15 65.04 74.25 65.95 70.02 69.72 72.91
Research and Development Expense of Revenue
4.13% 4.24% 3.97% 3.93% 3.67% 3.59% 3.28% 3.12% 3.24% 3.14%
Selling, General and Administrative Expense of Revenue
27.20% 26.31% 24.87% 24.05% 21.51% 20.42% 20.02% 19.71% 20.04% 19.60%
Intangible Assets out of Total Assets
0.77 0.74 0.72 0.68 0.56 0.65 0.60 0.61 0.63 0.59
Share Based Compensation of Revenue
0.73% 0.76% 0.74% 0.71% 0.61% 0.59% 0.68% 0.65% 0.70% 0.70%
Graham Net Nets
(0.31) (0.29) (0.20) (0.13) (0.07) (0.13) (0.13) (0.13) (0.13) (0.13)
Graham Number
79.34 90.44 106.17 124.19 177.64 213.90 211.86 205.60 219.98 238.01
Earnings Yield
3.57% 2.93% 3.26% 2.84% 3.45% 2.94% 3.21% 2.85% 3.19% 3.07%
Free Cash Flow Yield
5.00% 4.60% 4.26% 3.14% 3.70% 2.59% 3.20% 3.34% 3.69% 2.90%
Revenue per Share
46.26 52.96 60.59 63.86 81.36 99.52 114.58 111.03 112.25 118.19
Operating CF per Share
8.25 10.14 11.30 12.43 20.93 23.63 23.35 21.78 22.69 20.74
Capex per Share
(1.06) (1.27) (1.76) (2.22) (3.70) (6.35) (5.66) (3.61) (3.52) (3.93)
Free Cash Flow per Share
7.19 8.87 9.54 10.21 17.23 17.28 17.69 18.17 19.17 16.81
Cash per Share
1.99 3.38 5.23 6.00 26.07 11.36 21.74 20.93 14.58 26.80
Shareholders Equity per Share
54.53 64.34 68.62 74.19 87.16 103.69 112.33 121.05 129.71 141.68
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
54.53 64.34 68.62 74.19 87.16 103.69 112.33 121.05 129.71 141.68
Free Cash Flow
2,840.00 3,504.00 3,835.00 4,083.00 6,823.00 6,809.00 6,935.00 7,014.00 7,324.00 6,337.00
Working Capital
2,155.00 2,373.00 4,478.00 5,696.00 11,653.00 6,677.00 8,219.00 10,577.00 8,805.00 13,518.00
Capital Expenditures
(418.00) (501.00) (708.00) (890.00) (1,466.00) (2,503.00) (2,219.00) (1,392.00) (1,343.00) (1,481.00)
Net Current Asset Value
(17,347.00) (21,835.00) (18,021.00) (16,813.00) (12,578.00) (34,155.00) (27,893.00) (27,413.00) (25,633.00) (28,221.00)
EV/EBIT
29.02 31.68 27.91 31.48 24.79 28.99 28.27 34.01 30.28 31.52
Capex to Sales
0.02 0.02 0.03 0.03 0.05 0.06 0.05 0.03 0.03 0.03
Price to Operating Income
23.09 25.75 23.78 28.29 23.67 26.22 25.84 30.62 27.08 28.20
Other line items
Depreciation/Fixed assets
0.68 0.50 0.54 0.48 0.39 0.31 0.36 0.36 0.33 0.26
Cash ROIC
7.53% 7.68% 8.09% 8.31% 10.67% 8.77% 8.51% 8.15% 8.70% 6.38%
Accounts Receivable Turnover
5.90 5.73 6.08 6.02 6.39 5.72 5.58 5.25 5.23 5.21
Accounts Payable Turnover
11.33 9.75 8.87 8.04 7.92 7.76 8.30 8.24 8.46 7.85
Inventory Turnover
4.71 4.43 4.52 4.46 4.38 4.31 4.86 4.80 5.00 5.06
Average Days of Payables
34.13 45.44 43.66 49.30 48.96 53.46 47.57 40.70 44.64 50.23
Days of Inventory on Hand
81.57 94.54 81.24 86.54 90.70 94.19 79.26 72.10 72.17 75.24
Average Receivables
3,095.00 3,653.00 4,007.50 4,242.50 5,045.00 6,859.00 8,046.00 8,168.00 8,206.00 8,545.50
Average Payables
874.10 1,177.00 1,521.50 1,767.50 2,047.50 2,521.00 3,124.00 3,126.50 2,975.50 3,350.50
Average Inventory
2,102.35 2,592.00 2,988.00 3,187.50 3,699.50 4,540.00 5,342.50 5,361.00 5,033.00 5,201.50
Average Assets
43,371.15 51,288.50 56,450.50 57,306.50 63,716.50 82,087.50 96,138.50 97,940.00 98,023.50 103,832.00
Average Common Equity
21,445.10 23,476.50 26,499.50 28,630.50 32,096.00 37,686.00 42,443.50 45,378.00 48,138.00 51,483.00

Fold the line items

Columns are period end dates